Mode of transmisison: droplet

Incubation: 1-3d

Period of infectivity: 1-2d before symptoms start until d5 of illness

Vaccines: inactivated split virion vaccines (disrupted)

• Influvac

• Fluarix

• if had egg protein - anaphylaxis

• should hvae under specialist supervision

Schedule:

aged >65yo, pregnant women, age \<65 with high risk conditions, \<5yo who have been hospitalised for resp

efficacy: varied = 50-75% \<65; >65 non fata 28%, ILI 39%, influenza 49%

Herd: some evidence may be able to be achieved

• influenza A

  • H - haemagglutinin - responsible fore cell surface attachment during infection

  • N - neuraminidase - potentiates release of new virions from cell

clinical

• contagious

• reproductive number 1.4 - 4

• peak viral shedding @ 3d after developemnt of symptoms

• abrupt onset

  • fever

  • chills

  • malaise

  • headache

  • myalgia

  • non-productive cough

  • rhinitis

  • sore thorat

  • mild conjunctivitis

  • v/d

• range of severity

• pandemic strains cause more morbitiy/motality compared to seasonal or influenza B

High risk

• cardiovasuclar disease

  • iHD

  • CHF

  • Rheumatic heart disease

  • Congenital heart disease

  • cerebrovascular disease

• Respiratory

  • asthma - if on regular preventative

  • if impaired lung function

• DM

• chronic renal disease

• cancer - excluding non invasive skin cancer

• other conditions

• pregnant

• \<5 hospitalised for respiratory illness or have histoyr of significant respiratory illness

Guillain Barre

• small increase following seasonal influenza

• risk substantially less than risk of developing severe complications